Cardiovascular Risk in Philadelphia-Negative Myeloproliferative Neoplasms: Mechanisms and Implications-A Narrative...

Area of Science:

• Hematology
• Cardiology
• Oncology

Background:

• Myeloproliferative neoplasms (MPNs) like polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF) involve clonal hematopoiesis.
• Key genetic mutations include JAK2 V617F, MPL, and CALR, contributing to disease pathogenesis.
• MPNs are associated with a significant predisposition to thrombotic events and reduced survival, particularly in PMF.

Purpose of the Study:

• To review current research on the cardiovascular implications of MPNs.
• To highlight the mechanisms linking MPNs to cardiovascular disease, including thrombosis and inflammation.
• To emphasize the importance of understanding these associations for therapeutic development.

Main Methods:

• Literature review of recent research on MPNs and cardiovascular disease.
• Analysis of mechanisms contributing to cardiovascular risk in MPN patients.
• Synthesis of findings on thrombotic risk, inflammation, and vascular changes.

Main Results:

• MPNs significantly elevate cardiovascular risk via thrombotic events and chronic inflammation.
• Cytokine release from abnormal cells exacerbates atherosclerosis and vascular remodeling.
• MPN complications such as pulmonary hypertension and cardiac fibrosis worsen cardiovascular outcomes.

Conclusions:

• MPNs present substantial cardiovascular risks, necessitating focused clinical attention.
• Targeted therapies addressing inflammation and thrombosis are crucial for improving MPN patient outcomes.
• Further research into the MPN-cardiovascular nexus is vital for advancing patient care.